JAK-STAT signaling circuits in myocarditis and dilated cardiomyopathy

Herz

Volumn 32, Issue 6, 2007, Pages 474-481

  Ruppert, Volker ^b   Meyer, Thomas ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b Philipps Universität Marburg ^*

Author keywords

Dilated cardiomyopathy; Myocarditis; Signal transduction; STAT; Transcription factors

Indexed keywords

JANUS KINASE; STAT PROTEIN;

CELL MEMBRANE; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; ECHOCARDIOGRAPHY; HEART VENTRICLE ARRHYTHMIA; HUMAN; INNATE IMMUNITY; MYOCARDITIS; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; VIRUS INFECTION;

ANIMALS; CARDIOMYOPATHY, DILATED; HUMANS; JANUS KINASES; MODELS, CARDIOVASCULAR; MYOCARDITIS; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS;

EID: 34648837642     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00059-007-3040-x     Document Type: Review

References (75)

1. Kühl U, Noutsias M, Seeberg B, et al. Chronic inflammation in the myocardium of patients with clinically suspected dilated cardiomyopathy. J Card Fail 1994;1:13-25.
2. Magnani JW, Dec GW. Myocarditis. Current trends in diagnosis and treatment. Circulation 2006;113:876-90.
3. Ellis CR, Di Salvo T. Myocarditis. Basic and clinical aspects. Cardiol Rev 2007;15:170-7.
4. Mason JW. Viral latency: a link between myocarditis and dilated cardiomyopathy? J Mol Cell Cardiol 2002;34:695-8.
5. Mason JW. Myocarditis and dilated cardiomyopathy. An inflammatory link. Cardiovasc Res 2003;60:5-10.
6. Kühl U, Pauschinger M, Noutsias M, et al. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with "idiopathic" left ventricular dysfunction. Circulation 2005;111:887-93.
7. Mahrholdt H, Wagner A, Deluigi CC, et al. Presentation, patterns of myocardial damage, and clinical couse of viral myocarditis. Circulation 2006;114:1581-90.
8. Mason JW, O'Connor JB, Herskowitz A, et al. A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med 1995;333:269-75.
9. Li Y, Heuser JS, Cunningham LC, et al. Mimicry and antibody-mediated cell signaling in autoimmune myocarditis. J Immunol 2006;177:8234-40.
10. Caforio AL, Mahon NJ, Tona F, et al. Circulating cardiac autoantibodies in dilated cardiomyopathy and myocarditis: pathogenetic and clinical significance. Eur J Heart Fail 2002;4:411-7.
11. Caforio AL, Calabrese F, Angelini A, et al. A prospective study of biopsy-proven myocarditis: prognostic relevance of clinical and aetiopathogenetic features at diagnosis. Eur Heart J 2007;28:1326-33.
12. Maisch B, Outzen H, Roth D, et al. Prognostic determinants in conventionally treated myocarditis and perimyocarditis. Focus on antimyolemmal antibodies. Eur Heart J 1991;12:Suppl:81-7.
13. Lauer B, Schwannwell M, Kühl U, et al. Antimyosin autoantibodies are associated with deterioration of systolic and diastolic left ventricular function in patients with chronic myocarditis. J Am Coll Cardiol 2000;35:11-8.
14. Ishiyama S, Hiroe M, Nishikawa T, et al. The Fas/Fas ligand system is involved in the pathogenesis of autoimmune myocarditis in rats. J Immunol 1998;161:4695-701.
15. Seko Y, Kayagaki N, Seino K, et al. Role of Fas/FasL pathway in the activation of infiltrating cells in murine acute myocarditis caused by Coxsackievirus B3. J Am Coll Cardiol 2002;39:1399-403.
16. Sheppard R, Bedi M, Kubota T, et al., IMAC Investigators. Myocardial expression of Fas and recovery of left ventricular function in patients with recent-onset cardiomyopathy. J Am Coll Cardiol 2005;46:1036-42.
17. Maekawa Y, Ouzounian M, Opavsky MA, et al. Connecting the missing link between dilated cardiomyopathy and viral myocarditis: virus, cytoskeleton, and innate immunity. Circulation 2007;115:5-8.
18. Ihle JN. The Stat family in cytokine signaling. Curr Opin Cell Biol 2001;13:211-7.
19. Levy DE, Darnell JE Jr. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 2002;3:651-62.
20. Shuai K, Liu B. Regulation of JAK-STAT signalling in the immune system. Nat Rev Immunol 2003;3:900-11.
21. Barry SP, Townsend PA, Latchman DS, et al. Role of JAK-STAT pathway in myocardial injury. Trends Mol Med 2006;13:82-9.
22. Shuai K, Liao J, Song MM. Enhancement of antiproliferative activity of gamma interferon by the specific inhibition of tyrosine dephosphorylation of Stat1. Mol Cell Biol 1996;16:4932-41.
23. Vinkemeier U, Cohen SL, Moarefi I, et al. DNA binding of in vitro activated Stat1 alpha, Stat1 beta and truncated Stat1: interaction between NH2-terminal domains stabilizes binding of two dimers to tandem DNA sites. EMBO J 1996;15:5616-26.
24. Meyer T, Hendry L, Begitt A, et al. A single residue modulates tyrosine dephosphorylation, oligomerization, and nuclear accumulation of Stat transcription factors. J Biol Chem 2004;279:18998-9007.
25. Horvath CM, Stark GR, Kerr IM, et al. Interactions between STAT and non-STAT proteins in the interferon-stimulated gene factor 3 transcription complex. Mol Cell Biol 1996;16:6957-64.
26. Horvath CM, Wen Z, Darnell JE Jr. A STAT protein domain that determines DNA sequence recognition suggests a novel DNA-binding domain. Genes Dev 1995;15:984-94.
27. Yang E, Henriksen MA, Schaefer O, et al. Dissociation time from DNA determines transcriptional function in a STAT1 linker mutant. J Biol Chem 2002;277:13455-62.
28. Shuai K, Stark GR, Kerr IM, et al. A single phosphotyrosine residue of Stat91 required for gene activation by interferon-gamma. Science 1993;261:1744-6.
29. Schindler C, Shuai K, Prezioso VR, et al. Interferon-dependent tyrosine phosphorylation of a latent cytoplasmic transcription factor. Science 1992;257:809-13.
30. Rane SG, Reddy EP. Janus kinases: components of multiple signaling pathways. Oncogene 2000;19:5662-79.
31. Stark GR, Kerr IM, Williams BR, et al. How cells respond to interferons. Annu Rev Biochem 1998;67:227-64.
32. Shuai K, Horvath CM, Huang LH, et al. Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions. Cell 1994;76:821-8.
33. Haspel RL, Salditt-Georgieff M, Darnell JE Jr. The rapid inactivation of nuclear tyrosine phosphorylated Stat1 depends upon a protein tyrosine phosphatase. EMBO J 1996;15:6262-8.
34. Ten Hoeve J, de Jesus Ibarra-Sanchez M, Fu Y, et al. Identification of a nuclear Stat1 protein tyrosine phosphatase. Mol Cell Biol 2002;22:5662-8.
35. Meyer T, Begitt A, Lödige I, et al. Constitutive and IFNγ-induced nuclear import of STAT1 proceed through independent pathways. EMBO J 2002;21:344-54.
36. Marg A, Shan Y, Meyer T, et al. Nucleocytoplasmic shuttling by nucleoporins Nup153 and Nup214 and CRM1-dependent nuclear export control the subcellular distribution of latent Stat1. J Cell Biol 2004;21:823-33.
37. Zeng R, Aoki Y, Yoshida M, et al. Stat5B shuttles between cytoplasm and nucleus in a cytokine-dependent and -independent manner. J Immunol 2002;168:4567-75.
38. Pranada AL, Metz S, Herrmann A, et al. Real time analysis of STAT3 nucleocytoplasmic shuttling. J Biol Chem 2004;279:15114-23.
39. Sekimoto T, Nakajima K, Tachibana T, et al. Interferon-gamma-dependent nuclear import of Stat1 is mediated by the GTPase activity of Ran/TC4. J Biol Chem 1996;271:31017-20.
40. Bischoff FR, Scheffzek K, Ponstingl H. How Ran is regulated. Results Probl Cell Differ 2002;35:49-66.
41. Sekimoto T, Imamoto N, Nakajima K, et al. Extracellular signal-dependent nuclear import of Stat1 is mediated by nuclear pore-targeting complex formation with NPI-1, but not Rch1. EMBO J 1997;16:7067-77.
42. Fagerlund R, Melén K, Kinnunen L, et al. Arginine/lysine-rich nuclear localization signals mediate interactions between dimeric STATs and importin alpha 5. J Biol Chem 2002;277:30072-8.
43. McBride KM, Banninger G, McDonald C, et al. Regulated nuclear import of the STAT1 transcription factor by direct binding of importin-alpha. EMBO J 2002;21:1754-63.
44. Melén K, Kinnunen L, Julkunen I. Arginine/lysine-rich structural element is involved in interferon-induced nuclear import of STATs. J Biol Chem 2001;276:16447-55.
45. Melén K, Fagerlund R, Franke J, et al. Importin ? nuclear localization signal binding sites for STAT1, STAT2, and influenza A virus nucleoprotein. J Biol Chem 2003;278:28193-200.
46. McBride KM, McDonald C, Reich NC. Nuclear export signal located within the DNA-binding domain of the STAT1 transcription factor. EMBO J 2000;19:6196-206.
47. Meyer T, Marg A, Lemke P, et al. DNA binding controls inactivation and nuclear accumulation of the transcription factor Stat1. Genes Dev 2003;17:1992-2005.
48. Andrews RP, Ericksen MB, Cunningham CM, et al. Analysis of the life cycle of stat6. Continuous cycling of STAT6 is required for IL-4 signaling. J Biol Chem 2002;277:36563-9.
49. Terrell AM, Crisostomo PR, Wairiuko GM, et al. JAK/STAT/SOCS signaling circuits and associated cytokine-mediated inflammation and hypertrophy in the heart. Shock 2006;26:226-34.
50. Linde A, Mosier D, Blecha F, et al. Innate immunity and inflammation. New frontiers in comparative cardiovascular pathology. Cardiovasc Res 2007;73:26-36.
51. Freed DH, Moon MC, Borowiec AM, et al. Cardiotrophin-1: expression in experimental myocardial infarction and potential role in post-MI wound healing. Mol Cell Biochem 2003;254:247-56.
52. Fuchs M, Hilfiker A, Kaminski K, et al. Role of interleukin-6 for LV remodeling and survival after experimental myocardial infarction. FASEB J 2003;17:2118-20.
53. Dawn B, Xuan YT, Guo Y, et al. IL-6 plays an obligatory role in late preconditioning via JAK-STAT signaling and upregulation of iNOS and COX-2. Cardiovasc Res 2004;64:61-71.
54. Negoro S, Kunisada K, Tone E, et al. Activation of JAK/STAT pathway transduces cytoprotective signal in rat acute myocardial infarction. Cardiovasc Res 2000;47:797-805.
55. Kunisada K, Negoro S, Tone E, et al. Signal transducer and activator of transcription 3 in the heart transduces not only a hypertrophic signal but a protective signal against doxorubicin-induced cardiomyopathy. Proc Natl Acad Sci U S A 2000;97:315-9.
56. Fujio Y, Kunisada K, Hirota H, et al. Signals through gp130 upregulate bcl-x gene expression via STAT1-binding cis-element in cardiac myocytes. J Clin Invest 1997;99:2898-905.
57. Negoro S, Kunisada K, Fujio Y, et al. Activation of signal transducer and activator of transcription 3 protects cardiomyocytes from hypoxia/ reoxygenation-induced oxidative stress through the upregulation of manganese superoxide dismutase. Circulation 2001;104:979-81.
58. Funamoto M, Fujio Y, Kunisada K, et al. Signal transducer and activator of transcription 3 is required for glycoprotein 130-mediated induction of vascular endothelial growth factor in cardiac myocytes. J Biol Chem 2000;275:10561-6.
59. Hattori R, Maulik N, Otani H, et al. Role of STAT3 in ischemic preconditioning. J Mol Cell Cardiol 2001;33:1929-36.
60. Osugi T, Oshima Y, Fujio Y, et al. Cardiac-specific activation of signal transducer and activator of transcription 3 promotes vascular formation in the heart. J Biol Chem 2002;277:6676-81.
61. Oshima Y, Fujio Y, Nakanishi T, et al. STAT3 mediates cardioprotection against ischemia/reperfusion injury through metallothionein induction in the heart. Cardiovasc Res 2005;65:428-35.
62. Hilfiker-Kleiner D, Hilfiker A, Fuchs M, et al. Signal transducer and activator of transcription 3 is required for myocardial capillary growth, control of interstitial matrix deposition, and heart protection from ischemic injury. Circ Res 2004;95:187-95.
63. Smith RM, Suleman N, Lacerda L, et al. Genetic depletion of cardiac myocyte STAT-3 abolishes classical preconditioning. Cardiovasc Res 2004;63:611-6.
64. Harada M, Qin Y, Takano H, et al. G-CSF prevents cardiac remodeling after myocardial infarction by activating the Jak-Stat pathway in cardiomyocytes. Nat Med 2005;11:305-11.
65. El-Adawi H, Deng L, Tramontano A, et al. The functional role of the JAK-STAT pathway in post-infarction remodeling. Cardiovasc Res 2003;57:129-38.
66. Stephanou A, Brar BK, Scarabelli TM, et al. Ischemia-induced STAT-1 expression and activation play a critical role in cardiomyocytes apoptosis. J Biol Chem 2000;275:10002-8.
67. McCormick J, Barry SP, Sivarajah A, et al. Free radical scavenging inhibits STAT phosphorylation after in vivo ischemia/reperfusion injury. FASEB J 2006;20:2115-7.
68. Stephanou A, Scarabelli TM, Townsend PA, et al. The carboxyl-terminal activation domain of the STAT-1 transcription factor enhances ischemia/reperfusion-induced apoptosis in cardiac myocytes. FASEB J 2002;16:1841-3.
69. Yajima T, Yasukawa H, Jeon ES, et al. Innate defense mechanism against virus infection within the cardiac myocyte requiring gp130-STAT3 signaling. Circulation 2006;114:2364-73.
70. Kunisada K, Tone E, Fujio Y, et al. Activation of gp130 transduces hypertrophic signals via STAT3 in cardiac myocytes. Circulation 1998;98:346-52.
71. Ancey C, Menet E, Corbi P, et al. Human cardiomyocyte hypertrophy induced in vitro by gp130 stimulation. Cardiovasc Res 2003;59:78-85.
72. Okuno M, Nakagawa M, Shimada M, et al. Expressional patterns of cytokines in a murine model of acute myocarditis: early expression of cardiotrophin-1. Lab Invest 2000;80:433-40.
73. Ruppert V, Meyer T, Pankuweit S, et al. Activation of STAT1 transcription factor precedes up-regulation of coxsackie-adenovirus receptor (CAR) during viral myocarditis. Cardiovasc Pathol 2007:in press.
74. Yasukawa H, Yajima T, Duplain H, et al. The suppressor of cytokine signaling-1 (SOCS1) is a novel therapeutic target for enterovirus-induced cardiac injury. J Clin Invest 2003;111:469-78.
75. Podewski EK, Hilfiker-Kleiner D, Hilfiker A, et al. Alterations in Janus kinase (JAK)-signal transducers and activators of transcription (STAT) signaling in patients with end-stage dilated cardiomyopathy. Circulation 2003;107:798-802.